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status. Methods: New ischemic stroke (ICD-10 code I63) patients (no previous 
stroke within one year) between April 1, 2006 and March 31, 2009 (N= 4,350) were 
followed for one year using hospital Discharge Abstract Database. The severity of 
the stroke was obtained from the ambulatory care database. Median hospital costs 
by CMG+ group were obtained from Alberta Health. Hospitals were classified as 
teaching, community large, community medium, and community small hospitals. 
Hospitals were also classified as comprehensive stroke centre, urban and rural 
primary stroke centres, and other urban and rural hospitals. The adjusted risk 
factors in Bayesian Model included sex, age, all disease-specific co-morbidities, 
and disease severity. The results for four hospital types and five stroke center cat-
egories were calculated using the observed/expected approach. Results: The 30 
days mortality rates (95% CI) were lowest for teaching hospitals 10.1% (9.0%-11.2%) 
and large community hospitals (10.0%; 8.3%-11.8%), and the small community 
hospitals had the highest mortality rates (12.8%; 9.9%-15.8%). The mean LOS (95% 
CI) varied from 21.7 (20.9-22.6) days in teaching hospitals to 34.2 (28.6-41.0) days 
in community medium hospitals. The community medium hospitals had signifi-
cantly higher costs ($62,400; $49,900-$78,000) than the community large hospitals 
($32,900; $29,900-$36,200) and teaching hospitals ($37,000; $34,900-$39,200). Both 
comprehensive stroke and urban stroke centers had lower 30 day mortality rates 
(95% CI): 9.9% (8.8%-11.1%) and 9.7% (7.3%-12.0%); shorter LOS 21.6 (20.7-22.5) 
and 25.0 (22.7-27.6) days; and medium levels of costs $39,300 ($36,100-$40,700), 
compared to other hospitals. ConClusions: The study shows the hospital type 
and stroke centre had limited effects on the mortality but significant impact on 
LOS and costs.
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objeCtives: Stroke is the third leading cause of mortality worldwide, with sig-
nificant associated acute care hospitalization costs. The objective of this literature 
review was to delineate the costing methodologies employed for the estimation of 
in-patient hospital costs of stroke. Methods: A PubMed search was performed 
using the keywords: hospitalization, cost analysis, acute stroke, and cost-effec-
tiveness; limited to publications in English from 2008 onwards. Inclusion criteria 
were patient-level data collection and detailed description of costing methodology 
applied. Cost-effectiveness and literature review studies were excluded. Results: 
In total 22 articles were included in the analysis. Cohort studies comprised 45% of 
the sample, followed by database analyses (32%), registered-based studies (9%), 
retrospective chart review studies (9%), and clinical trials (5%). Cost categories 
measured included direct medical costs (bed and staff, laboratory and imaging 
investigations, medications, rehabilitation and supportive nursing care), as well 
as indirect costs for the patients and their caregivers; in 2 studies the economic 
analysis was performed from a societal perspective. The resource utilization 
(excluding the database analyses) was identified in the medical records (80%), or 
from interviews (20%). Unit costs were primarily derived from national listings or 
hospital accounting files (36% each). The sample sizes (ranging from 100 to over 
60,000 patients), as well as the total costs (ranging from US$500 to US$150,000 per 
patient and from US$70 to US$13,000 per day) varied significantly, as a result of the 
heterogeneous cost variables described. ConClusions: Methodologies differed 
in approach, complexity and specific cost variables evaluated. Consequently, the 
total costs varied significantly across studies which makes direct comparisons of 
outcomes difficult. A trend towards more sophisticated economic analyses, such 
as real costs measured versus hospital reimbursement rates, or hospitalization 
costs before versus after stroke, was observed. A more standardized approach to 
evaluating in-patient costs of stroke care is warranted.
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objeCtives: Implantable loop recorders (ILR) are devices that continuously moni-
tor heart rhythm in patients with suspicion of cardiac arrhythmias. Reveal LinQ™ 
is a new insertable holter, an 87% smaller than Reveal® XT/DX that records abnor-
mal heart rhythm up to 3 years. The objective was to develop an economic tool 
which allows hospitals to quantify their cost savings from the simplified procedure 
of Reveal LinQ™. The tool was used to compare the costs of implanting Reveal® 
XT/DX in the cath lab to the costs of inserting Reveal LinQ™ out of the cath lab in 
three public hospitals of the Spanish National Health Care System. Methods: A 
cost model was developed to assess the cost per procedure of Reveal LinQ™ and 
Reveal® XT/DX. The model included data of the personnel needed in the proce-
dure, the hospital setting, the hospitalization previous to the procedure, remote 
monitoring and post-procedure controls. Results: The total process-related 
savings of LinQ™ vs. Reveal® XT/DX in Virgen de la Salud, Puerta de Hierro and 
Virgen de la Arrixaca Hospitals were € 335 (13.3%), € 365 (13.1%) and € 517 (19.2%), 
respectively. Reveal LinQ™ was associated with a 66% reduction in cardiologist 
and OR-assistant time in Virgen de la Salud Hospital, a reduction of 15 minutes 
of cardiologist time in Puerta de Hierro Hospital and a reduction of 3 control vis-
its due to remote monitoring in Virgen de la Arrixaca Hospital. ConClusions: 
The economic tool showed that the insertion of Reveal LinQ™ is associated 
with mean savings of € 406 from a hospital perspective compared to previous 
devices; mainly derived from moving the procedure out of the catheter lab, a 
reduction of the specialists’ time and in-hospital follow up visits due to remote 
monitoring.
in Greece a substantial increase of the households with at least one chronic condi-
tion patient which are subjected to CHE is recorded. There is a need for counter 
measures or/and an alternative policy context in order to reduce this catastrophic 
effect of economic crisis.
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objeCtives: Through CYP2C19, the antiplatelet clopidogrel and the proton-pump 
inhibitor esomeprazole demonstrate a pharmacokinetic interaction that could 
translate into clinical inefficacy of clopidogrel. No medical consensus has been 
reached to date and therefore different guidelines are available. We aimed to 
evaluate the prescribing practices in the University Hospitals of Geneva (HUG) by 
measuring if the co-prescription was staggered as suggested by experts. We also 
measured the Omeprazole-CLopidogrel-Aspirin (OCLA) study impact on clopi-
dogrel use in our hospital. Methods: Patient’s medical orders and nurse’s drug 
administration planning’s were analysed from January 2013 to April 2014 and the 
hospital pharmacy database from January 2000 to April 2014. To measure the “extra 
costs” of the implementation of different guidelines we built scenarios assum-
ing the clopidogrel or esomeprazole replacement with prasugrel or ticagrelor 
and pantozole or ranitidine, respectively. Results: Fifty seven percent of patients 
under clopidogrel had a co-prescription of esomeprazole during the study period. 
Among them 15% (154/1’000) had a medical order staggering the co-prescription 
(more than 10 hours apart), 16% a concomitant prescription and 64% no clear 
information. Five percent had 40 mg esomeprazole twice daily, hindering the 
possibility of staggering. Surprisingly we found a higher rate of patients hav-
ing a nurse’s schedule of more than 10 hours (39%, 417/1’071). Switching drugs 
would lead to increased costs for HUG of € 38’210 for prasugrel, € 34’800 for tica-
grelor, € 9’590 for pantoprazole and € 5’205 for ranitidine. A statistical significant 
decrease in trend of clopidogrel use was observed after the OCLA study publi-
cation. ConClusions: The medical order’s information time frame should be 
mandatory in order to improve the transmission throughout the whole informa-
tion system and allow a clear staggering of clopidogrel-esomperazole co-prescrip-
tion avoiding drug-drug interactions when possible. Nurses take the initiative 
to stagger the co-prescription when these are not clearly defined by medical 
orders.
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objeCtives: This study compares the outcome and health care performance 
among five health zones in Alberta by evaluating 30 days in-hospital mortality 
and length of stay (LOS) in patients with acute ischemic stroke, and total hospitali-
zation costs over one year. Methods: Ischemic stroke (ICD-10 code I63) patients 
(without previous stroke within one year, N= 1,445) hospitalized between April 
1, 2007 and March 31, 2008 were followed for one year using hospital Discharge 
Abstract Database. The severity of the stroke was obtained from the ambulatory 
care database (NACRs). Median hospital costs by CMG+ group were obtained from 
Alberta Health. Logistic regression was used to analyse in-hospital mortality; nega-
tive binomial regression assessed LOS, and generalized gamma model (log link) 
for hospital costs. The risk-adjusted outputs were estimated adjusting for sex, 
all disease-specific co-morbidities, and stroke severity. We calculated observed/
expected results for five zones; South, Calgary, Central, Edmonton, and North 
Zones. Results: The risk-adjusted 30-days-mortality rates (95% CI) varied from 
7.8% (3.4%-12.1%) to 13.5% (9.6%-17.4%) in South and Central zones, respectively. 
The adjusted mean LOS varied from 16.3 (13.8-19.3) days in South Zone to 26.7 
(24.2-29.5) and 29.3 (24.0-35.8) days in Edmonton and North zones, respectively. The 
results show several statistically significant differences between the first episodes 
LOS between zones reflecting partly differences in the post-acute care in each loca-
tion for patients not discharged to home. The one-year-mean hospitalization costs 
varied from $72,300 ($55,000-$95,100) in North Zone to $25,500 ($20,500-$31,800) in 
South Zone. ConClusions: The study shows significant variation in outcomes 
for ischemic stroke between the five health zones. Although the Provincial Stroke 
Strategy has largely standardized the stroke care between regions, differences in 
post-acute care arrangements have produced significant LOS and cost differences. 
More detailed analysis of the reasons for regional variation is needed for improve-
ment of the regional health care outcomes.
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objeCtives: This study examines the association of 30 day in-hospital mortality, 
length of stay (LOS) during the first hospital episode, and hospitalization costs 
during one year after acute ischemic stroke by type of hospital and by stroke centre 
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were to home, 25% to rehabilitative care then home, 2% to rehabilitative care then a 
nursing home, 7% to long-term care and 6% of stays ended with a patient death. Of 
a total cost over 1 year of € 610 million (mean cost per patient of € 20,326), 70% con-
cern the post-acute phase. By increasing the proportion of patients thrombolyzed, 
costs are reduced primarily by a decrease in rehabilitative care, with savings per 
additional treated patient of € 1,462. By adding improved timing, savings are more 
than doubled (€ 3,183 per additional patient). ConClusions: By improving throm-
bolytic management in stroke units, patient journeys through care pathways can 
be modified, with increased discharges home, a change in post-acute resource 
consumption and net savings.
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objeCtives: Regulatory hurdles for novel medical devices are lower in Europe 
than in the US. The costs and evidence requirements to achieve CE marking for 
class III devices are lower than to achieve FDA-approval via a PMA submission. As 
such, many companies have chosen to enter European markets with innovative 
cardiac devices before entering the US market. This study sought to understand 
the frequency with which that has occurred in the last 10 years, and the correlation 
between market access timing and cardiac outcomes. Methods: A review of CE 
mark and FDA approvals for class III implantable cardiac devices was conducted for 
the period of 2003-2013. Devices were identified and cross referenced to determine 
which products achieved both CE mark and FDA approval. Those with both, were 
then compared by the date of approval to determine market access variance in the 
US versus Germany. Publically available coverage and reimbursement policies were 
reviewed in each market in combination with relevant disease prevalence rates over 
the study period. Results: Implantable cardiac devices were routinely available in 
Germany before the US during the study period. Early use across Europe, in many 
cases, created additional evidence that was leveraged during the FDA approval and 
follow-on reimbursement assessment processes in the US. While HTAs for devices 
was relatively rare in Germany, similar rates of reimbursement and access were 
achieved in both markets. Rates of cardiovascular associated mortality have dropped 
dramatically, across both markets though rates initiated their decline earlier in 
Germany. ConClusions: Germans benefited from earlier access to many innova-
tive implantable cardiac devices during the period of 2003 to 2013, as compared to 
their American counterparts. The link between early access, clinical outcomes, and 
cost needs to be further analyzed in future studies.
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objeCtives: To identify cardiologists willing to participate in Health outcome or 
Clinical Studies Phase III/IV in internal medicine and to include patients for out-
come assessment. Real life and Peri/Post-Approval Studies are becoming more and 
more important to meet regulatory and market access needs. The objective of the 
present contribution is to assess the benefits of a managed panel of cardiologists 
for site and patient recruitment. Methods: In 2012, a representative survey among 
members of a managed physician panel of cardiologists in US, UK, GER, FR, IT and 
SP was conducted. 208 cardiologists reported on former experiences with clinical 
studies phase III/IV and other post-approval studies, their willingness to participate 
in future studies and their potential adherence to requirements of Good Clinical 
Practice rules. Results: 87,6% of the cardiologists reported to have formerly par-
ticipated in clinical studies phase III/IV, and 54,3% in post-approval studies. Over 
58% of these cardiologists were willing to participate in future studies (58,2% in 
clinical studies phase III/IV and 63,1% in other post-approval studies). More than 
92,7% of this group was ready to be named as principal investigator to an ethical 
committee, to report serious events to the sponsor (97,6%), or to participate in a 
web-based training session (90,3%). Within one month cardiologists see in average 
175 patients suffering from chronic heart disease in their practices (Minimum: 20; 
Maximum more than 500). 93,5% of the cardiologists are willing to ask their patients 
for informed consent for participation in studies, thereby providing a promising 
source for recruiting patients. ConClusions: Cardiologists from a managed panel 
are a time- and cost-effective option for recruiting sites and patients for obser-
vational post-approval outcome and safety studies in the big 5 EU countries and 
the US. Patient incidence estimates are a reliable source for enrollment planning.
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objeCtives: Demonstration of long-term value of preventive care in terms of health 
gains and avoided costs associated with disease progression may be of great value 
for those who need to prioritize health policies. This analysis aimed to evaluate 
physicians’ and primary care payers’ opinions about a user-friendly tool which esti-
mates long-term health gains following LDL-C reduction. Methods: A user-friendly 
tool was developed based on a previously published Markov model employed to 
evaluate health outcomes, including cardiovascular (CV) events and due costs. The 
model incorporated Framingham risk equations, Portuguese population characteris-
tics, national mortality rates and local costs. Software runs in iOS and the user may 
simulate for 3, 5 and 10 years the expected CV events drop following a given LDL-C 
PCV173
effeCt of oral nutrItIonal suPPlements on HosPItal outComes In 
PatIents aged 65+ wItH CongestIVe Heart faIlure
Lakdawalla D.1, Thornton Snider J.2, Perlroth D.3, LaVallee C.2, Linthicum M.T.2, Philipson T.J.4, 
Partridge J.5, Wischmeyer P.6
1University of Southern California, Los Angeles, CA, USA, 2Precision Health Economics, Los 
Angeles, CA, USA, 3Stanford University, Stanford, CA, USA, 4University of Chicago, Chicago, IL, 
USA, 5Abbott Nutrition, Columbus, OH, USA, 6University of Colorado School of Medicine, Aurora, 
CO, USA
objeCtives: Hospital admissions for congestive heart failure (CHF) are a major 
driver of costs for health systems, and CHF is especially prevalent in patients 
aged 65 and older. This study assessed whether provision of oral nutritional sup-
plements (ONS) in the hospital can reduce these costs, by estimating the effect 
of ONS use on 30-day readmission rates, length of stay (LOS), and hospitaliza-
tion episode costs. Methods: Using the 2000-2010 Premier Research database, 
a large US hospital episode database, we extracted a sample of episodes among 
patients aged 65 and older with a primary diagnosis of CHF. We excluded episodes 
involving tube feeding and those ending in death (due to censoring). Using pro-
pensity score matching, we created a 1: 1 matched sample of ONS and non-ONS 
episodes. We applied ordinary least squares (OLS) and instrumental variables 
(IV) regression analyses to investigate the outcomes of ONS use. The key out-
comes studied were 30-day readmission rates, LOS, and episode costs (measured 
in 2010 US$). Results: Propensity score matching produced a matched sample 
of 38,418 CHF episodes. Naïve OLS analysis, which did not account for selection 
bias, suggested that ONS increased costs, LOS, and probability of 30-day readmis-
sion. However, using IV regression analysis to control for selection bias revealed 
that ONS use reduced the probability of readmission within 30 days by 10.1%, 
from 0.387 to 0.360 (p< 0.01). LOS was reduced through ONS use by 1.28 days 
(14.2%), from 9.03 to 7.75 (p< 0.01). Episode costs were significantly lower with 
ONS use, reducing medical expenditures by $1,266 (7.8%), from $16,166 to $14,900 
(p< 0.01). ConClusions: In elderly patients hospitalized with CHF, ONS improves 
30-day readmission, LOS, and episode cost outcomes. ONS use could provide a 
low-cost strategy for improving hospitalization outcomes for elderly patients with 
CHF and reducing burden on health systems from CHF.
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objeCtives: The choice of stent used in percutaneous coronary intervention (PCI) 
is often at the discretion of the interventional cardiologist (IC) without informed 
shared decision making. We aim to assess the impact of ICs’ awareness of the risk of 
delayed arterial healing associated with drug-eluting stents (DES) on patient knowl-
edge transfer. Methods: 132 ICs from 11 countries (3 Asian: Malaysia, Hong Kong, 
Singapore and 8 European: Germany, Italy, UK, The Netherlands, Belgium, Denmark, 
Russia and Serbia) were invited to complete an online survey using a 4-point scale 
regarding their (i) familiarity with delayed arterial healing associated with DES; (ii) 
how concerned they are about delayed arterial healing; (iii) frequency they discuss 
this risk with their patients and (iv) frequency this risk influence the type of stent they 
use. Responses from Asian cardiologists were compared with Europeans. Results: 
43.2% ICs were Asians and 56.8% were Europeans. Majority of IC were extremely/
very familiar with the risk of delayed arterial healing after DES implantation (63.2% 
Asian vs. 56.0% European, p= NS). IC who were extremely/very concerned about the 
risk of delayed healing were more likely to discuss with their patients (Odds Ratio 
(OR) 2.62, 95% confidence interval (CI) 1.17-5.85, p< 0.01) and influence their stent 
choice (OR 5.56,95%CI 2.56-12.05, p< 0.01). Although twice as many Asian compared 
to European ICs were extremely/very concerned about delayed arterial healing with 
DES (59.6% vs. 32.4%, respectively, p< 0.01), there were no significant differences in the 
frequency this risk was discussed with patients (often/always: 24.6% Asian vs. 26.7% 
European, P= NS) or influence the type of stent used (often/always: 47.4% vs. 35.7%, 
P= NS). ConClusions: Many patients are not well informed of the risk associated 
with DES despite high level of physician awareness and concern of this risk. This 
knowledge transfer gap exists in both Asia and Europe.
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objeCtives: This study aims to evaluate the current management and associ-
ated costs of acute ischemic stroke (AIS) for patients admitted in stroke units 
in France and over a 1 year follow-up period as well as to assess the impact 
of improved thrombolytic management in terms of increasing the proportion 
of patients receiving thrombolysis and/or treated within 3hrs from symptom 
onset on functional recovery and care pathways. Methods: A decision model 
was developed, comprising two components: the first corresponding to the acute 
hospital management phase of patients with AIS up until hospital discharge and 
the second corresponding to the post-acute phase. Patient journeys and costs were 
determined for both phases. Improved thrombolytic management was modeled 
by increasing the proportion of patients receiving thrombolysis from the current 
estimated level of 16.7 to 25% as well as subsequently increasing the proportion of 
patients treated within 3 hours of the onset of symptoms post-stroke from 50 to 
100%. The impact on care pathways was derived from clinical data. Results: In 
2011, 29,999 stays took place in a stroke unit for AIS in France. 60% of discharges 
